PARTRUBIX Trademark

Trademark Overview

On Thursday, July 1, 2021, a trademark application was filed for PARTRUBIX with the United States Patent and Trademark Office. The USPTO has given the PARTRUBIX trademark a serial number of 90807543. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, July 22, 2024. This trademark is owned by BeiGene, Ltd.. The PARTRUBIX trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals for the treatment of cancer, autoimmune and inflammatory diseases and infectious diseases
partrubix

General Information

Serial Number90807543
Word MarkPARTRUBIX
Filing DateThursday, July 1, 2021
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, July 22, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 26, 2022

Trademark Statements

Goods and ServicesPharmaceuticals for the treatment of cancer, autoimmune and inflammatory diseases and infectious diseases
Pseudo MarkPART RUBIK

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, September 13, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBeiGene, Ltd.
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressSan Mateo, CA 94404
Party NameBeiGene, Ltd.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressGrand Cayman KY1-1108
KY

Trademark Events

Event DateEvent Description
Monday, September 13, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, July 5, 2021NEW APPLICATION ENTERED
Tuesday, March 22, 2022ASSIGNED TO EXAMINER
Thursday, March 24, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 6, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, November 2, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, April 26, 2022PUBLISHED FOR OPPOSITION
Tuesday, April 26, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 21, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, November 2, 2022SOU EXTENSION 1 FILED
Wednesday, November 2, 2022SOU EXTENSION 1 GRANTED
Thursday, December 8, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, November 4, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, December 8, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, December 8, 2022TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, December 8, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, December 8, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, May 8, 2023SOU TEAS EXTENSION RECEIVED
Monday, May 8, 2023SOU EXTENSION 2 FILED
Monday, May 8, 2023SOU EXTENSION 2 GRANTED
Wednesday, May 10, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, November 1, 2023SOU EXTENSION 3 GRANTED
Wednesday, November 1, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, November 1, 2023SOU EXTENSION 3 FILED
Friday, November 3, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 22, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, July 22, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED

Related Keywords

partrubix diseases infectious inflammatory autoimmune treatment cancer pharmaceuticals